Anzeige
+++InnoCan Pharma: Hat dieses Unternehmen die Lösung aller CBD-Probleme für Merck & Co?+++

GALAPAGOS GENOMICS WKN: A0EAT9 ISIN: BE0003818359 Kürzel: GLPG Forum: Aktien Thema: Hauptdiskussion

Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
52,39 EUR
-0,78 %-0,41
23. May, 10:13:02 Uhr, Lang & Schwarz
Kommentare 92
Summer.76
Summer.76, 10. Mai 5:54
0
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value https://www.benzinga.com/general/biotech/22/05/27086970/rbc-expects-business-development-to-unlock-this-pharma-stocks-balance-sheet-value ... • Business Development primarily involves deals or collaborations around early-stage assets rather than later-stage or large acquisitions and openness to indications outside of areas GLPG has worked historically.  • RBC senses a collaborative tone towards partner Gilead Sciences Inc (NASDAQ:GILD), though it believes the deal structure between the parties may need some tuning for optimal value creation.  • With the strategic review of the internal and external pipeline still evolving, the analysts expect shares to trade in line.  • The analysts raised the price target to $62 from $60 on model updates. ...
Summer.76
Summer.76, 6. Mai 16:05
0
https://www.glpg.com/press-release/3599/galapagos-demonstrates-regulatory-and-commercial-progress-in-q1-2022
Summer.76
Summer.76, 28. Mär 18:01
0
https://www.streetinsider.com/dr/news.php?id=19828975&gfv=1 Galapagos NV (GLPG) Announces Jyseleca Approved in Japan Galapagos NV (NASDAQ: GLPG) reports that Gilead Sciences K.K. (Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan) and EA Pharma Co., Ltd. (Tokyo, Japan) today announced the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW), of a second indication for Jyseleca (filgotinib), a once-daily, oral, JAK1 preferential inhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). ...
Summer.76
Summer.76, 24. Feb 22:26
0
Galapagos 2021 results set stage for future growth https://finance.yahoo.com/news/galapagos-2021-results-set-stage-210100025.html ... Financial results in 2021: • Group net revenues of €484.8 million as compared to €478.1 million in 2020 • Operating loss of €165.6 million as compared to €178.6 million in 2020 • Net loss of €103.2 million as compared to €305.4 million in 2020 • Cash and current financial investments of €4.7 billion on 31 December 2021 • Operational cash burni of €564.8 million, within the guided range ...
Summer.76
Summer.76, 27.01.2022 14:57
1
Galapagos appoints Paul Stoffels as Chief Executive Officer https://www.globenewswire.com/news-release/2022/01/26/2373804/0/en/Galapagos-appoints-Paul-Stoffels-as-Chief-Executive-Officer.html Galapagos creates 1M subscription rights https://seekingalpha.com/news/3792170-galapagos-creates-1m-subscription-rights-stock-rises-9 Galapagos (NASDAQ:GLPG) said its supervisory board created 1M subscription rights under a new plan for the benefit of a company personnel. The subscription rights have an exercise term of eight years and an exercise price of €50. Paul Stoffels will ultimately become the new subscription right holder under the scheme.
Summer.76
Summer.76, 15.11.2021 17:15
1
https://www.globenewswire.com/news-release/2021/11/15/2334506/0/en/Jyseleca-filgotinib-approved-in-the-European-Union-for-the-treatment-of-ulcerative-colitis.html Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis ...announced today that the European Commission has granted marketing authorization for Jyseleca® (filgotinib 200mg tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
F
FlyHigh2021, 07.11.2021 10:17
0
Wird bestimmt bald was kommen in Sachen CEO
Bützbuster
Bützbuster, 06.11.2021 14:47
1
Neuer CEO und CSO dann up....
Summer.76
Summer.76, 05.11.2021 5:13
1
Galapagos reports commercial and operational progress at Q3 financial results https://www.globenewswire.com/news-release/2021/11/04/2328165/0/en/Galapagos-reports-commercial-and-operational-progress-at-Q3-financial-results.html • First nine months 2021 financial results: • Group revenues of €317.9 million • Operating loss of €175.7 million • Net loss of €119.6 million • Cash and current financial investments of €4.9 billion on 30 September 2021 • Filgotinib launch in RA on track with reimbursement secured in 14 countries • Reduced 2021 cash burn guidance by €50 million to €530-€570 million ...
Bützbuster
Bützbuster, 22.09.2021 18:26
0
Sitzen am 5 Mrd Cash. Schöne Phase 3 Bude muss da kommen.... mindestens
Bützbuster
Bützbuster, 22.09.2021 18:25
0
Neuer CEO in den nächsten Wochen und eine millionenschwere Akquisition
F
FlyHigh2021, 21.09.2021 20:49
0
Bützbuster was erwartest du?
Bützbuster
Bützbuster, 20.09.2021 17:06
0
Klarer Buy and Hold
Summer.76
Summer.76, 17.09.2021 15:43
0
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS https://finance.yahoo.com/news/galapagos-announces-positive-chmp-opinion-111500365.html
Bützbuster
Bützbuster, 16.09.2021 12:27
0
52w low. Erneuter buy.
Bützbuster
Bützbuster, 07.09.2021 6:52
0
Bisher noch keine PR

Meistdiskutiert

Kommentare
1 CHIMERIX Hauptdiskussion +14,71 %
2 BAVARIAN NORDIC Hauptdiskussion -3,92 %
3 DAX Hauptdiskussion -0,35 %
4 Ocugen Aktienforum Hauptdiskussion -0,46 %
5 DEUTSCHE BANK Hauptdiskussion +1,34 %
6 Trading- und Aktien-Chat
7 Dax Prognose -0,35 %
8 STEINHOFF INT.HLDG.EO-,50 Hauptdiskussion +0,64 %
9 AMC ENTERTAINMENT Hauptdiskussion +1,31 %
10 VALNEVA SE Hauptdiskussion +0,23 %
Alle Diskussionen

Aktien

Kommentare
1 CHIMERIX Hauptdiskussion +14,71 %
2 BAVARIAN NORDIC Hauptdiskussion -6,23 %
3 Ocugen Aktienforum Hauptdiskussion -0,46 %
4 DEUTSCHE BANK Hauptdiskussion +2,40 %
5 STEINHOFF INT.HLDG.EO-,50 Hauptdiskussion +0,64 %
6 AMC ENTERTAINMENT Hauptdiskussion +0,49 %
7 VALNEVA SE Hauptdiskussion +0,32 %
8 MV OIL TRUST DL-,01 Hauptdiskussion -2,07 %
9 Biontech Speedliner +0,13 %
10 GAZPROM Hauptdiskussion ±0,00 %
Alle Diskussionen
Werbung
Ihre kurzfristige Erwartung an GLPG
GLPG steht am  bei
Veränderung:  
mgl. Rendite mit
Hebel (Omega)
Zum Produkt